Abstract: A method for forming a multi-layer packaging laminate including the following steps in the mentioned order: i) providing a polyolefin film as a base layer of the laminate, wherein the base layer forms a first outer most polymer surface of the laminate, ii) applying a first polymer layer arrangement in a flowable state onto the base layer at a first application station, the first polymer layer arrangement having at least one polymer layer, iii) transporting the base layer with the applied first polymer layer arrangement to a further application station, iv) applying a second polymer layer arrangement onto the first polymer layer arrangement at the further application station, the second polymer layer arrangement having at least one polymer layer, wherein the second polymer layer arrangement forms a second outermost polymer surface of the laminate, wherein at least one of the first and the second polymer layer arrangement contains a water vapor and/or oxygen transmission polymer barrier layer, wherein the se

Abstract: The invention provides method of guiding unidirectional movement of a cell comprising exposing the cell to a surface comprising an asymmetric, three-dimensional pattern of one or a plurality of topographical elements for a time period sufficient to bias actin polymerization within the cell. The invention also provides methods of inducing directional movement of a cell, and methods of harnessing an actin wave within a cell. In addition, the invention provides compositions comprising a contact side, wherein at least a portion of the contact side comprises a cell contact portion comprising an asymmetric, three-dimensional pattern of one or a plurality of topographical elements, and methods of inducing healing of a wound of a subject comprising contacting the wound with the composition.

Abstract: A method for displaying a modified phase mask on a spatial light modulator (SLM), including: modifying, by a processor, a phase mask by combining the phase mask with a virtual lens pattern, the virtual lens pattern having a focal length; displaying, by the SLM in communication with the processor, the modified phase mask on the SLM; and projecting, by a light source in communication with the processor, the light source through the SLM to form an intensity pattern at a distance from the SLM corresponding to the focal length of the virtual lens pattern, the intensity pattern being based on the phase mask.

Abstract: A method for displaying a modified phase mask on a spatial light modulator (SLM), including: modifying, by a processor, a phase mask by combining the phase mask with a virtual lens pattern, the virtual lens pattern having a focal length; displaying, by the SLM in communication with the processor, the modified phase mask on the SLM; and projecting, by a light source in communication with the processor, the light source through the SLM to form an intensity pattern at a distance from the SLM corresponding to the focal length of the virtual lens pattern, the intensity pattern being based on the phase mask.

Abstract: The invention provides method of guiding unidirectional movement of a cell comprising exposing the cell to a surface comprising an asymmetric, three-dimensional pattern of one or a plurality of topographical elements for a time period sufficient to bias actin polymerization within the cell. The invention also provides methods of inducing directional movement of a cell, and methods of harnessing an actin wave within a cell. In addition, the invention provides compositions comprising a contact side, wherein at least a portion of the contact side comprises a cell contact portion comprising an asymmetric, three-dimensional pattern of one or a plurality of topographical elements, and methods of inducing healing of a wound of a subject comprising contacting the wound with the composition.

Abstract: An apparatus and method apply magnetic fields by generators external to a body or body part with sensors within an in vivo source that are sensitive to applied magnetic fields Through the use of these applied magnetic fields and sensitive sensors, disclosed embodiments can realize much better spatial resolution than is conventionally possible.

Abstract: To facilitate adjusting a bearing arrangement, particularly in a wind turbine, for different operating situations, the bearing arrangement has an adjusting device with which the bearing preload can be adjusted starting from a base preload. This can allow, for example signs of wear to be compensated, manufacturing tolerances or design inaccuracies to be corrected and in particular current loading states to be addressed. This design avoids the otherwise usual overdimensioning of the bearing arrangement, thereby increasing the efficiency of the wind turbine as well as the service life of the bearing arrangement.

Abstract: To facilitate adjusting a bearing arrangement, particularly in a wind turbine, for different operating situations, the bearing arrangement has an adjusting device with which the bearing preload can be adjusted starting from a base preload. This can allow, for example signs of wear to be compensated, manufacturing tolerances or design inaccuracies to be corrected and in particular current loading states to be addressed. This design avoids the otherwise usual overdimensioning of the bearing arrangement, thereby increasing the efficiency of the wind turbine as well as the service life of the bearing arrangement.

Abstract: A method is provided for electrochemically depositing a polymer with spatial selectivity. A substrate having a substrate surface is contacted with an aqueous solution containing a selectively insolubilizable polysaccharide, such as chitosan, which is subjected to electrochemically treatment to deposit, with spatial selectivity, the selectively insolubilizable polysaccharide on a patterned electrically conductive portion of the substrate surface.

Abstract: A method is provided for electrochemically depositing a polymer with spatial selectivity. A substrate having a substrate surface is contacted with an aqueous solution containing a selectively insolubilizable polysaccharide, such as chitosan, which is subjected to electrochemically treatment to deposit, with spatial selectivity, the selectively insolubilizable polysaccharide on a patterned electrically conductive portion of the substrate surface.

Abstract: The disclosure relates to novel 1.alpha.,7.alpha.-dithio-substituted spirolactones of general Formula I ##STR1## wherein R.sup.1 is C.sub.1-3 -alkyl and C.sub.1-3 -acyl andR.sup.2 is hydrogen, C.sub.1-3 -alkyl and C.sub.1-3 -acyl,to their preparation, and to their use as medicinal agents.The compounds of this invention exhibit anti-aldosterone activity and show the profile of effectiveness of a pro-drug.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is (a) hydrogen, (b) C.sub.1-10 alkyl, (c) C.sub.1-10 alkyl substituted by halogen; C.sub.1-4 alkoxy; C.sub.6-10 aryl; C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; di-C.sub.1-4 -alkylamino; or tri-C.sub.1-4 -alkylammonium, (d) C.sub.4-10 cycloalkyl, (e) C.sub.4-10 cycloalkyl substituted by C.sub.1-4 alkyl, (f) C.sub.6-10 aryl, (g) C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S;A is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--;W is hydroxymethylene, RO-methylene, CH.sub.3 or CH.sub.3, ##STR2## wherein OH or OR is in the .alpha.- or .beta.

Abstract: Novel 7.alpha.-substituted 3-oxo-17.alpha.-pregn-4-ene-21,17-carbolactones of the formula ##STR1## wherein ##STR2## is a CC single or CC double bond or the group ##STR3## R.sup.7 is the group SR', R' being a hydrogen atom or a straight-chain or branched alkyl residue of 1-6 carbon atoms optionally substituted by a hydroxy or acyloxy group, the group COOR" or the group COR" wherein R" is an alkyl group of 1-4 carbon atoms and ##STR4## is a CC single bond or the group ##STR5## have antialdosterone activity with reduced endocrinological side effects.

Abstract: New 15,16-methylene-17.alpha.-pregna-4,6-diene-21-carboxylic acid salts of formula I ##STR1## wherein R.sup.1 and R.sup.2 each alone is hydrogen or together they form an additional CC bond or a methylene group,M is an alkali metal,and the methylene group in the 15,16 position is in the .alpha. or .beta. position, in addition to having a strong antialdosterone effect, have reduced antiandrogenic and progestogenic side effects.

Abstract: Compounds of the formula I ##STR1## wherein R.sub.1 is ##STR2## wherein R.sup.I and R.sup.II each independently is alkyl of 1-4 carbon atoms, or R.sup.I and R.sup.II together with the connecting N-atom form a 5- or 6-membered heterocyclic ring whose remaining atoms are all C-atoms, or which also includes and additional N-atom, an additional O or S atom or a combination thereof; ##STR3## wherein R.sup.I and R.sup.II are as defined above; --SR.sup.III, wherein R.sup.III is methyl, ethyl or phenyl; or--OR.sup.IV, wherein R.sup.IV is methyl, ethyl, propyl, methoxymethyl, allyl, or .beta.-dimethylaminoethyl;R.sub.2 is hydrogen, methyl, or ethyl; ##STR4## wherein the wavy lines mean that the substituent is in the .alpha.- or .beta.-position, and ##STR5## M is Na, K or Li; and R.sup.V, R.sup.VI, R.sup.VII and R.sup.VIII each independently is alkyl of 1-4 carbon atoms, have valuable pharmacological properties, e.g., a combination of antiprogestational and antimineralocorticordal effects.

Abstract: 7.alpha.-acylthio-1.alpha.,2.alpha.-methylene-3-oxo-17.alpha.-pregn-4-ene-2 1,17-carbolactones of Formula I ##STR1## wherein ##STR2## and R is a lower saturated acyl radical of 2 to 4 carbon atoms,have a stronger antialdosterone effect and lower side effects than spironoloctone.

Abstract: 7.alpha.-acylthio-15,16-methylene-3-oxo-17.alpha.-pregna-1,4-diene-21,17-ca rbolactones of the formula ##STR1## wherein the 15,16-methylene group can be in the .alpha.- or .beta.-configuration, andR is a lower alkyl residue,have altialdosterone activity.They are prepared from corresponding .DELTA..sup.4 -unsaturated compounds by chemical or microbiological 1,2-dehydrogenation.

Abstract: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is (a) hydrogen, (b) C.sub.1-10 alkyl, (c) C.sub.1-10 alkyl substituted by halogen; C.sub.1-4 alkoxy; C.sub.6-10 aryl; C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; di-C.sub.1-4 -alkylamino; or tri-C.sub.1-4 alkylammonium; (d) C.sub.4-10 cycloalkyl, (e) C.sub.4-10 cycloalkyl substituted by C.sub.1-4 alkyl, (f) C.sub.6-10 aryl, (g) C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S;W is hydroxymethylene or RO-methylene; or ##STR2## wherein OH or OR is in the .alpha.

Abstract: Compounds of the formula ##STR1## wherein the 15,16-methylene group is in the .alpha.- or .beta.-position, andE is ##STR2## are useful as diuretics.

Abstract: Stabilized prostacyclins having a wide range of pharmacological activity and long duration of such activity, have the formula ##STR1## wherein R.sub.1 is (a) OR.sub.3, wherein R.sub.3 is hydrogen, alkyl, cycloalkyl, aryl or a heterocyclic residue; or (b) NHR.sub.4 wherein R.sub.4 is an acid residue;B is straight-chain or branched alkylene of 2-10 carbon atoms;A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, trans--CH.dbd.CH-- or --C.tbd.C--,W is free or functionally modified hydroxymethylene or free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position; D and E together are a direct bond; orD is straight-chain or branched alkylene of 1-5 carbon atoms; andE is oxygen or sulfur or a direct bond,R.sub.2 is alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group; andR.sub.5 is free or functionally modified hydroxy; and when R.sub.3 is hydrogen, the salts thereof with physiologically compatible bases.